“Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of science is valuable for public health and for Niagen Bioscience (NAGE),” remarked Rob Fried, CEO of Niagen Bioscience. “We believe the FDA’s latest reversal of previous rulings on the DSHEA drug preclusion rule relating to NMN could serve to increase awareness of the NAD+ precursor market overall and the safety and efficacy of Niagen, in particular. Also, it is important to note that NMN products being sold on the market infringe upon an existing patent portfolio.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience’s Niagen IV, injections now available at iCRYO clinics
- Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience
- Niagen Bioscience price target raised to $12 from $11 at H.C. Wainwright
- Niagen Bioscience’s Robust Growth and Strategic Initiatives Drive Buy Rating
- Niagen Bioscience Reports Strong Q2 Growth and Outlook